0
Signin
countryflagUS

18889881171

AAPL 169.3 -0.6047% MSFT 395.125 1.4885% GOOG 165.555 0.5558% GOOGL 163.795 0.6235% AMZN 178.86 2.2057% NVDA 830.03 -3.9339% META 439.1 2.0759% TSLA 179.995 -1.7923% TSM 134.94 -1.7475% LLY 776.75 -0.5569% V 267.29 -0.4914% AVGO 1242.86 -4.4152% JPM 191.86 0.0626% UNH 484.11 0.0848% NVO 129.21 0.7014% WMT 58.82 -0.893% LVMUY 164.02 -0.0792% XOM 116.06 -1.8686% LVMHF 822.33 -0.4443% MA 442.07 -2.0235%

GlycoMimetics Inc

Healthcare US GLYC

1.62USD
-0.18(10.00%)

Last update at 2024-05-01T20:03:00Z

Day Range

1.621.93
LowHigh

52 Week Range

1.114.16
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -46.68800M -63.42700M -51.02700M -57.89200M -48.27400M
Minority interest - - - - -
Net income -93.32860M -63.14240M -50.27425M -54.11577M -48.27400M
Selling general administrative 19.09M 17.11M 16.74M 14.36M 11.41M
Selling and marketing expenses - - - - -
Gross profit 0.07M 1.16M 10.16M - 0.00000M
Reconciled depreciation 0.21M 0.26M 0.27M 0.28M 0.28M
Ebit -47.61015M -63.71160M -51.77975M -61.66823M -51.78012M
Ebitda -47.40300M -63.44700M -51.50900M -61.38900M -51.50500M
Depreciation and amortization 0.21M 0.26M 0.27M 0.28M 0.28M
Non operating income net other - - - - -
Operating income -47.40300M -63.44700M -51.50900M -61.38900M -51.50500M
Other operating expenses 47.48M 64.61M 61.67M 61.39M 51.51M
Interest expense 46.64M 0.02M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 0.71M 0.02M 0.48M 3.50M 3.23M
Net interest income 0.71M 0.02M 0.48M 3.50M 3.23M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 46.64M -0.28460M -0.75275M -3.77623M 3.23M
Total revenue 0.07M 1.16M 10.16M 0.00000M 0.00000M
Total operating expenses 47.48M 64.61M 61.67M 61.39M 51.51M
Cost of revenue - - - - 0.00000M
Total other income expense net 0.71M 0.02M 0.48M 3.50M 3.23M
Discontinued operations - - - - -
Net income from continuing ops -46.68836M -63.42744M -51.02690M -57.89191M -48.27363M
Net income applicable to common shares -46.68880M -63.42744M -51.02690M -57.89191M -48.27363M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 51.81M 94.35M 142.83M 167.97M 214.84M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.84M 533.80M 1238.33M 4326.32M 1.94M
Total liab 8.88M 12.74M 14.61M 13.77M 9.38M
Total stockholder equity 42.93M 81.60M 128.22M 154.20M 205.46M
Deferred long term liab - - - - 0.61M
Other current liab 6.99M 8.72M 9.44M 8.71M 6.10M
Common stock 0.05M 0.05M 0.05M 0.04M 0.04M
Capital stock 0.05M 0.05M 0.05M 0.04M 0.04M
Retained earnings -419.58579M -372.89699M -309.46955M -258.44265M -200.55074M
Other liab - - 0.26M - 0.61M
Good will - - - - -
Other assets 0.00041M 1.61M -0.00017M 0.00032M -0.00027M
Cash 47.87M 90.25M 137.03M 158.20M 209.92M
Cash and equivalents - - - - -
Total current liabilities 8.88M 11.82M 12.43M 10.95M 8.76M
Current deferred revenue - - - - -
Net debt -46.95244M -88.33499M -134.21644M -154.57836M -209.91800M
Short term debt 0.92M 1.00M 0.90M 0.80M -
Short long term debt - - - - -
Short long term debt total 0.92M 1.92M 2.82M 3.62M -
Other stockholder equity 462.46M 454.45M 437.64M 412.60M 407.56M
Property plant equipment 0.99M 1.95M 0.62M 0.82M 0.96M
Total current assets 50.71M 90.25M 138.27M 162.53M 212.27M
Long term investments - - - - -
Net tangible assets 42.93M 81.60M 128.22M 154.20M 205.46M
Short term investments - - - - -
Net receivables 0.14M 0.00135M 0.00215M 0.19M 0.41M
Long term debt - - - - -
Inventory -0.14440M -533.80535M -1237.09180M -4322.18119M -0.00040M
Accounts payable 0.97M 2.11M 2.09M 1.44M 2.66M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -1.86155M -1.58364M
Additional paid in capital - - - - -
Common stock total equity - - 0.05M 0.04M 0.04M
Preferred stock total equity - - - - -
Retained earnings total equity - - -309.46955M -258.44265M -200.55074M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.10M 2.15M 1.61M 1.61M 1.61M
Deferred long term asset charges - - - - -
Non current assets total 1.10M 4.09M 4.56M 5.44M 2.57M
Capital lease obligations 0.92M 1.92M 2.82M 3.62M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.08419M -0.01494M -0.06851M -0.14493M -0.12562M
Change to liabilities -1.13742M 0.02M 1.38M 1.48M 0.57M
Total cashflows from investing activities -0.08419M -0.01494M -0.06851M -0.14493M -0.12562M
Net borrowings - - - - -
Total cash from financing activities 4.16M 10.72M 18.14M 0.41M 129.45M
Change to operating activities -3.52450M -1.18287M 3.28M 0.02M 0.06M
Net income -46.68880M -63.42744M -51.02690M -57.89191M -48.27363M
Change in cash -42.38427M -46.78013M -21.16642M -51.71615M 85.99M
Begin period cash flow 90.25M 137.04M 158.20M 209.92M 123.92M
End period cash flow 47.87M 90.25M 137.04M 158.20M 209.92M
Total cash from operating activities -46.45749M -57.48953M -39.24193M -51.98414M -43.33113M
Issuance of capital stock 4.16M 10.70M 17.82M 0.00000M 128.43M
Depreciation 0.21M 0.26M 0.27M 0.28M 0.28M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - 18.14M 0.41M 129.45M
Other cashflows from financing activities -0.08419M 0.03M 0.32M 0.41M 1.02M
Change to netincome 4.69M 6.84M 6.90M 6.22M 4.59M
Capital expenditures 0.08M 0.01M 0.07M 0.14M 0.13M
Change receivables - - - - -
Cash flows other operating - - 3.23M -2.06862M -0.48752M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - -21.16642M -51.71615M 85.99M
Change in working capital -4.66192M -1.16519M 3.93M -1.20662M 0.08M
Stock based compensation 3.86M 6.09M 6.90M 6.22M 4.59M
Other non cash items 0.83M 0.75M 0.68M 0.62M 0.00017M
Free cash flow -46.54168M -57.50447M -39.31044M -52.12907M -43.45675M

Fundamentals

  • Previous Close 1.80
  • Market Cap137.16M
  • Volume978566
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-40.13136M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.07M
  • Diluted EPS TTM-0.63

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GLYC
GlycoMimetics Inc		 -0.18 10.00% 1.62 - - 1154.60 2.74 555.40 -1.9712
NVO
Novo Nordisk A/S		 0.90 0.70% 129.21 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.312 2.55% 126.46 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 9.33 2.38% 402.14 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 -0.46 0.51% 89.14 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

GlycoMimetics Inc

9708 Medical Center Drive, Rockville, MD, United States, 20850

Key Executives

Name Title Year Born
Mr. Harout Semerjian CEO, Pres & Director 1970
Mr. Brian M. Hahn Sr. VP & CFO 1974
Dr. John L. Magnani Ph.D. Sr. VP of Research & Chief Scientific Officer 1953
Ms. Stephanie R. Irish CPA VP of Accounting 1971
Mr. Christian Dinneen-Long VP, Corp. Counsel & Corp. Sec. NA
Mr. Armand Girard Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel. 1969
Mr. Bruce Johnson Sr. VP & Chief Commercial Officer NA
Dr. Edwin Rock M.D., Ph.D. Chief Medical Officer NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).